On Nov 13, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $160 to $175.
J.P. Morgan analyst Rachel Vatnsdal maintains with a buy rating, and adjusts the target price from $135 to $160.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and adjusts the target price from $145 to $175.
Baird analyst Catherine Ramsey Schulte maintains with a buy rating, and adjusts the target price from $120 to $160.
CCORF analyst Kyle Mikson CFA maintains with a buy rating, and adjusts the target price from $150 to $165.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
Natera has delivered another robust quarter, according to an analyst. With a strong performance across volume, selling price, margin, and cash management, the company is perceived as operating effectively, with potential for further enhancement leading into 2025. The consensus is that Natera stands out as one of the most distinguished entities in the diagnostics sector.
Natera's Q3 results significantly exceeded expectations, continuing to enhance its core fundamentals. The company is strategically reinvesting its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
The company recorded another robust quarter with its sales, margins, and cash flow all surpassing expectations.
Natera's third quarter revenue and gross margins exceeded estimates, showing robust performance. The company's progress is widespread, highlighted by a 60% annual increase in Signatera clinical volume growth and significant gains within women's health accounts.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.